Home
About Journal
Editorial Board
Instruction
Subscribe
Download
Contact Us
Chinese
中国医学创新
2025
,
Vol. 22
Issue (27)
: 135-139
DOI
: 10.3969/j.issn.1674-4985.2025.27.032
Experiential exchange
Current Issue
|
Archive
|
Adv Search
|
Clinical Study of Combined Treatment with Tislelizumab and GC Chemotherapy Regimen for Bladder Cancer
YANG Yongsheng, HUANG Bo, QIU Changying
First-author's address: Department of Urology, Yingtan City People's Hospital, Yingtan 335000, China
Abstract
Figure/Table
References
Related Citation (15)
Download:
PDF
(1462 KB)
HTML
(1 KB)
Export:
BibTeX
|
EndNote
(RIS)
Received:
19 June 2025
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Cite this article:
URL:
http://www.zgyxcx.com/EN/10.3969/j.issn.1674-4985.2025.27.032
OR
http://www.zgyxcx.com/EN/Y2025/V22/I27/135
[1]
ZHAO Gang,PEI Yawei.
The Impact of Transurethral Resection of Bladder Tumor Combined with Epirubicin Hyperthermic Intravesical Chemotherapy on Prognosis in Non-Muscle-Invasive Bladder Cancer
[J]. 中国医学创新, 2025, 22(9): 1-5.
© 2016 中国医学创新 editorial
Address: Beijing south cellular road number five Postcodes: 100055